Andrew Zheng, Yao Li MD PhD & Stephen H Tsang MD PhD (2015)
Personalized therapeutic strategies for patients with retinitis pigmentosa, Expert Opinion on Biological Therapy, 15:3, 391-402, DOI: 10.1517/14712598.2015.1006192
When the above article was first published, the reference annotation for reference 41 was incorrect. The annotation read that this reference was “the first to show that genetic defects in patient-specific, iPSC-derived retinal cells can be successfully corrected in vitro with gene therapy, a crucial step in a potential autologous transplantation treatment scheme.” However, this is incorrect as the first article to show this was Cereso et al in Molecular Therapy - Methods and Clinical Development that was published April 20141.
The sentence on page 400 under reference 41 should read:
“This paper demonstrates the utility of iPSCs in research involving both new therapies as well as disease mechanisms. It is the first to show that electrophysiological defects in patient-specific iPSC-derived retinal cells can be successfully corrected in vitro with gene therapy, a crucial step in a potential autologous transplantation treatment scheme.”
The authors apologize for this error.
1. Cereso N, Pequignot MO, Robert L et al. Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient. Mol Ther Methods Clin Dev. 2014 Apr 2;1:14011. doi: 10.1038/mtm.2014.11. eCollection 2014.